Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nithya Gajendran

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Scientific Reports|November 7, 2024
Transcriptomic analysis of melanoma cells reveals an association of α-synuclein with regulation of the inflammatory responseSanthanasabapathy Rajasekaran, Siyuan Cheng, Nithya Gajendran, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 28, 2024
Targeting HDAC6 improves anti-CD47 immunotherapyMaria Gracia-Hernandez, Ashutosh S Yende, Nithya Gajendran, et al.
Science Advances|November 15, 2024
The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapyDamian Kovalovsky, Satish Noonepalle, Manasa Suresh, et al.
Journal of Medicinal Chemistry|May 29, 2026
Macrophage-Centric Phenotypic Screening Identifies Tetrazolone-Based HDAC6 Inhibitors That Reprogram the Tumor Immune Microenvironment and Improve Immune Checkpoint BlockadeNithya Gajendran, Manasa Suresh, Sebastian J Marquez R, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Scientific Reports|November 7, 2024
Transcriptomic analysis of melanoma cells reveals an association of α-synuclein with regulation of the inflammatory responseSanthanasabapathy Rajasekaran, Siyuan Cheng, Nithya Gajendran, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 28, 2024
Targeting HDAC6 improves anti-CD47 immunotherapyMaria Gracia-Hernandez, Ashutosh S Yende, Nithya Gajendran, et al.
Science Advances|November 15, 2024
The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapyDamian Kovalovsky, Satish Noonepalle, Manasa Suresh, et al.
Journal of Medicinal Chemistry|May 29, 2026
Macrophage-Centric Phenotypic Screening Identifies Tetrazolone-Based HDAC6 Inhibitors That Reprogram the Tumor Immune Microenvironment and Improve Immune Checkpoint BlockadeNithya Gajendran, Manasa Suresh, Sebastian J Marquez R, et al.
Pageof 1